128102-80-7

Basic information

• Product Name: 2-METHYL-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE
• Synonyms: 2-METHYL-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE
• CAS NO: 128102-80-7
• Molecular Formula: C₈H₇N₃O
• Molecular Weight: 161.16068
• EINECS: -0
• Mol File: 128102-80-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-METHYL-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYL-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE(128102-80-7)
• EPA Substance Registry System: 2-METHYL-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE(128102-80-7)

Safety Data

• Hazardous Substances Data: 128102-80-7(Hazardous Substances Data)

Upstream product

• 617-35-6 2-oxo-propionic acid ethyl ester 
• 452-58-4 2,3-Diaminopyridine 
• 155629-95-1 7-bromo-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one 
• 165615-64-5 (R)-2-methyl-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one 
• 54231-35-5 3-fuoro-2-nitropyridine 
• 856970-14-4 (7-bromo-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2-yl)-acetic acid ethyl ester 
• 169692-49-3 7-bromo-2-ethoxycarbonylmethylene-1,2-dihydro-4H-pyrido<2,3-b>pyrazin-3-one 
• 38875-53-5 5-bromo-pyridine-2,3-diamine 
• 169692-47-1 2-ethoxycarbonylmethylene-1,2-dihydro-4H-pyrido<2,3-b>pyrazin-3-one 
• 127-17-3 2-oxo-propionic acid 
• 1825-45-2 2,2-dihydroxypropanoic acid 

Downstream Products

• 1613148-80-3 2-methyl-4-[2-(5-methyl-1-phenyl-1H-benzimidazol-2-yl)ethyl]pyrido[2,3-b]pyrazin-3(4H)-one 
• 1552286-92-6 C₁₉H₁₈ClN₅O₂ 
• 1552286-91-5 C₁₉H₁₆ClN₅O₂ 
• 1552286-86-8 C₂₁H₂₀ClN₅O₂ 
• 1552286-63-1 C₁₉H₁₈ClN₅O₂ 
• 1552286-61-9 C₁₈H₁₆ClN₅O₂ 
• 1552286-60-8 C₁₈H₁₆ClN₅O₂ 
• 1552286-59-5 C₁₇H₁₄ClN₅O₂ 
• 1552286-58-4 C₂₀H₂₀ClN₅O₂ 
• 1552286-57-3 C₁₈H₁₆ClN₅O₂ 
• 1552286-41-5 C₁₈H₁₄ClN₅O₃ 
• 1552286-23-3 C₂₁H₁₈ClN₅O₂ 
• 1552286-43-7 C₁₅H₁₀ClN₅O 
• 1426833-14-8 1-(2,6-dichloro-4-iodo-phenyl)-4-methyl-2,3,5,9,9b-pentaazacyclopenta[a]naphthalene 

Relevant articles and documents

Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β

Traditional fragment-based drug discovery (FBDD) relies heavily on structural analysis of the hits bound to their targets. Herein, we present a complementary approach based on diversity-oriented synthesis (DOS). A DOS-based fragment collection was able to produce initial hit compounds against the target GSK3β, allow the systematic synthesis of related fragment analogues to explore fragment-level structure-activity relationship, and finally lead to the synthesis of a more potent compound.

4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES

The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

PYRIDINE COMPOUNDS AND USES THEREOF

The present invention is directed to pyridine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psych